First prize: direct real-time temperature monitoring for laparoscopic and CT-guided radiofrequency ablation of renal tumors between 3 and 5 cm.

PURPOSE

To evaluate our experience with radiofrequency ablation (RFA) of renal tumors in the range of 3 to 5 cm.

PATIENTS AND METHODS

A series of 96 patients underwent 104 tumor laparoscopic or percutaneous CT-guided RFAs. We identified 37 tumors between 3 and 5 cm at the time of the ablation. Non-conducting temperature probes, independent of the radiofrequency (RF) electrode, were placed at the peripheral and deep margins of the tumor in order to achieve real-time temperature monitoring of the ablation zone. All ablations were continued until the peripheral and deep temperature probes reached 60 degrees C.

RESULTS

All 37 patients (100%) achieved complete necrosis at the initial session. There were two radiographic failures at 9 months and 30 months that required a second treatment (95% radiographic success rate). Tissue samples taken at the time of the re-treatment (one partial nephrectomy with numerous biopsies of the deep and peripheral margins and one repeat ablation with eight core biopsies) showed no evidence of viable tumor with hematoxylin and eosin or nicotinamide adenine dinucleotide viability stains. The average length of follow-up was 11.3 months (range 1-44 months). No patient with localized disease at the time of the RFA developed local extension or metastatic disease in follow-up.

CONCLUSIONS

The majority of renal tumors between 3 and 5 cm can be ablated with complete necrosis in a single session. Placement of independent temperature probes at the peripheral and deep margins of the tumor provides real-time monitoring that assists in the deployments of the RF electrode and determining the appropriate duration of the ablation cycles. Attention to real-time thermometry decreases the need for repeat sessions to achieve complete necrosis for larger tumors. Likewise, real-time thermometry decreases the incidence of overtreatment of normal parenchyma and prevents collateral damage to adjacent vital structures (ureter, pancreas, bowel, spleen, nerves) outside the desired zone of ablation.